U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H14F3NO2
Molecular Weight 249.2296
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENETHYLAMINE

SMILES

COC1=CC(CCN)=C(OC)C=C1C(F)(F)F

InChI

InChIKey=LYXGNMLWYONZID-UHFFFAOYSA-N
InChI=1S/C11H14F3NO2/c1-16-9-6-8(11(12,13)14)10(17-2)5-7(9)3-4-15/h5-6H,3-4,15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C11H14F3NO2
Molecular Weight 249.2296
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7996545 | https://www.ncbi.nlm.nih.gov/pubmed/20481515 | https://www.ncbi.nlm.nih.gov/pubmed/18666267

2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is the alpha-methylated analogue of 2C-TFM, a psychedelic drug of the phenethylamine and amphetamine chemical classes. 2,5-Dimethoxy-4-trifluoromethylamphetamine acts as an nanomolar agonist at the 5HT2A and 5HT2C receptors and possess hallucinogenic effects in humans.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
33.0 nM [Ki]
2225.0 nM [Ki]
3.78 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

0.3 mg as a single dose
Route of Administration: Oral
In Vitro Use Guide
The frontal cortex or hippocampal brain regions from 20-40 rats were pooled and homogenized in 4 or 8 volumes of 0.32 M sucrose for frontal cortex or hippocampus, respectively. The homogenates were centrifuged at 36000g for 10 min, and the resulting pellets were resuspended in the same volume of sucrose. All experiments were performed with triplicate determinations using the appropriate buffer to which 200-400 mkg of protein was added, giving a final volume of 1 mL. The tubes were allowed to equilibrate for 15 min at 37 C before filtering through Whatman GF/C filters using a cell harvester followed by two 5 mL washes using icecold Tris buffer. Specific binding was defined as that displaceable with 10 mkM cinanserin in both the [3H]ketanserin and [125I]DOI binding study and with 10 mkM 5-HT in the [3H]-8-OH-DPAT binding study. Filters were air-dried and placed into scintillation vials with 10 mL of Ecolite scintillation cocktail and allowed to sit overnight before counting at an efficiency of 37% for tritium and directly counted in a y counter for [125I]-labeled ligand at an efficiency of 79.4%.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:26:52 GMT 2023
Edited
by admin
on Sat Dec 16 09:26:52 GMT 2023
Record UNII
16O4G6IKYL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENETHYLAMINE
Systematic Name English
2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)-BENZENEETHANAMINE
Systematic Name English
2C-TFM
Common Name English
BENZENEETHANAMINE, 2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)-
Systematic Name English
Code System Code Type Description
WIKIPEDIA
2C-TFM
Created by admin on Sat Dec 16 09:26:52 GMT 2023 , Edited by admin on Sat Dec 16 09:26:52 GMT 2023
PRIMARY 2C (2C-x) is a general name for the family of psychedelic phenethylamines containing methoxy groups on the 2 and 5 positions of a benzene ring. Most of these compounds also carry lipophilic substituents at the 4 position, usually resulting in more potent and more metabolically stable and longer acting compounds. Most of the currently known 2C compounds were first synthesized by Alexander Shulgin in the 1970s and 1980s, and published in his book, PiHKAL (Phenethylamines i Have Known And Loved). Dr. Shulgin also invented the term 2C, being an acronym for the 2 carbon atoms between the benzene ring and the amino group.[1] Shulgin, Alexander; Ann Shulgin (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
FDA UNII
16O4G6IKYL
Created by admin on Sat Dec 16 09:26:52 GMT 2023 , Edited by admin on Sat Dec 16 09:26:52 GMT 2023
PRIMARY
CAS
159277-08-4
Created by admin on Sat Dec 16 09:26:52 GMT 2023 , Edited by admin on Sat Dec 16 09:26:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID70439308
Created by admin on Sat Dec 16 09:26:52 GMT 2023 , Edited by admin on Sat Dec 16 09:26:52 GMT 2023
PRIMARY
PUBCHEM
10399795
Created by admin on Sat Dec 16 09:26:52 GMT 2023 , Edited by admin on Sat Dec 16 09:26:52 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY